TY - JOUR
T1 - Advancing drug discovery through assay development
T2 - a survey of tool compounds within the human solute carrier superfamily
AU - Digles, Daniela
AU - Ingles-Prieto, Alvaro
AU - Dvorak, Vojtech
AU - Mocking, Tamara A.M.
AU - Goldmann, Ulrich
AU - Garofoli, Andrea
AU - Homan, Evert J.
AU - Di Silvio, Alberto
AU - Azzollini, Lucia
AU - Sassone, Francesca
AU - Fogazza, Mario
AU - Bärenz, Felix
AU - Pommereau, Antje
AU - Zuschlag, Yasmin
AU - Ooms, Jasper F.
AU - Tranberg-Jensen, Jeppe
AU - Hansen, Jesper S.
AU - Stanka, Josefina
AU - Sijben, Hubert J.
AU - Batoulis, Helena
AU - Bender, Eckhard
AU - Martini, Riccardo
AU - IJzerman, Adriaan P.
AU - Sauer, David B.
AU - Heitman, Laura H.
AU - Manolova, Vania
AU - Reinhardt, Juergen
AU - Ehrmann, Alexander
AU - Leippe, Philipp
AU - Ecker, Gerhard F.
AU - Huber, Kilian V.M.
AU - Licher, Thomas
AU - Scarabottolo, Lia
AU - Wiedmer, Tabea
AU - Superti-Furga, Giulio
N1 - Funding Information:
The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This work was performed by the RESOLUTE ( https://re-solute.eu/ ), REsolution ( https://re-solute.eu/resolution ), and EUbOPEN ( https://www.eubopen.org/ ) consortia. Plasmids are available through Addgene ( https://www.addgene.org/depositor-collections/re-solute/ ). RESOLUTE has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 777372. This joint undertaking receives support from the European Union\u2019s Horizon 2020 Research and Innovation Program and the EFPIA. REsolution has received funding from Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 101034439. This joint undertaking receives support from the European Union\u2019s Horizon 2020 Research and Innovation Program and the EFPIA. EUbOPEN has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875510. The joint undertaking receives support from the European Union\u2019s Horizon 2020 Research and Innovation Program, the EFPIA, Ontario Institute for Cancer Research, Royal Institution for the Advancement of Learning\u2013McGill University, Kungliga Tekniska Hoegskolan, and Diamond Light Source Limited. This article reflects only the authors\u2019 views, and neither the IMI nor the European Union and the EFPIA are responsible for any use that may be made of the information contained therein.
Publisher Copyright:
Copyright © 2024 Digles, Ingles-Prieto, Dvorak, Mocking, Goldmann, Garofoli, Homan, Di Silvio, Azzollini, Sassone, Fogazza, Bärenz, Pommereau, Zuschlag, Ooms, Tranberg-Jensen, Hansen, Stanka, Sijben, Batoulis, Bender, Martini, IJzerman, Sauer, Heitman, Manolova, Reinhardt, Ehrmann, Leippe, Ecker, Huber, Licher, Scarabottolo, Wiedmer and Superti-Furga.
PY - 2024/7/9
Y1 - 2024/7/9
N2 - With over 450 genes, solute carriers (SLCs) constitute the largest transporter superfamily responsible for the uptake and efflux of nutrients, metabolites, and xenobiotics in human cells. SLCs are associated with a wide variety of human diseases, including cancer, diabetes, and metabolic and neurological disorders. They represent an important therapeutic target class that remains only partly exploited as therapeutics that target SLCs are scarce. Additionally, many small molecules reported in the literature to target SLCs are poorly characterized. Both features may be due to the difficulty of developing SLC transport assays that fulfill the quality criteria for high-throughput screening. Here, we report one of the main limitations hampering assay development within the RESOLUTE consortium: the lack of a resource providing high-quality information on SLC tool compounds. To address this, we provide a systematic annotation of tool compounds targeting SLCs. We first provide an overview on RESOLUTE assays. Next, we present a list of SLC-targeting compounds collected from the literature and public databases; we found that most data sources lacked specificity data. Finally, we report on experimental tests of 19 selected compounds against a panel of 13 SLCs from seven different families. Except for a few inhibitors, which were active on unrelated SLCs, the tested inhibitors demonstrated high selectivity for their reported targets. To make this knowledge easily accessible to the scientific community, we created an interactive dashboard displaying the collected data in the RESOLUTE web portal (https://re-solute.eu). We anticipate that our open-access resources on assays and compounds will support the development of future drug discovery campaigns for SLCs.
AB - With over 450 genes, solute carriers (SLCs) constitute the largest transporter superfamily responsible for the uptake and efflux of nutrients, metabolites, and xenobiotics in human cells. SLCs are associated with a wide variety of human diseases, including cancer, diabetes, and metabolic and neurological disorders. They represent an important therapeutic target class that remains only partly exploited as therapeutics that target SLCs are scarce. Additionally, many small molecules reported in the literature to target SLCs are poorly characterized. Both features may be due to the difficulty of developing SLC transport assays that fulfill the quality criteria for high-throughput screening. Here, we report one of the main limitations hampering assay development within the RESOLUTE consortium: the lack of a resource providing high-quality information on SLC tool compounds. To address this, we provide a systematic annotation of tool compounds targeting SLCs. We first provide an overview on RESOLUTE assays. Next, we present a list of SLC-targeting compounds collected from the literature and public databases; we found that most data sources lacked specificity data. Finally, we report on experimental tests of 19 selected compounds against a panel of 13 SLCs from seven different families. Except for a few inhibitors, which were active on unrelated SLCs, the tested inhibitors demonstrated high selectivity for their reported targets. To make this knowledge easily accessible to the scientific community, we created an interactive dashboard displaying the collected data in the RESOLUTE web portal (https://re-solute.eu). We anticipate that our open-access resources on assays and compounds will support the development of future drug discovery campaigns for SLCs.
KW - KNIME
KW - solute carrier
KW - tool compound
KW - transport assay
KW - transport protein
UR - http://www.scopus.com/inward/record.url?scp=85199131575&partnerID=8YFLogxK
U2 - 10.3389/fphar.2024.1401599
DO - 10.3389/fphar.2024.1401599
M3 - Article
AN - SCOPUS:85199131575
VL - 15
JO - Frontiers in Pharmacology
JF - Frontiers in Pharmacology
SN - 1663-9812
M1 - 1401599
ER -